QuidelOrtho Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2197981051
USD
27.82
1.29 (4.86%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About QuidelOrtho Corp. stock-summary
stock-summary
QuidelOrtho Corp.
Pharmaceuticals & Biotechnology
Quidel Corp. is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: rapid immunoassays, cardiac immunoassay, specialized diagnostic solutions and molecular diagnostic solutions. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of many diseases and medical conditions, including infectious diseases, cardiovascular diseases and conditions, women’s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Amplivue, Lyra and Thyretain.
Company Coordinates stock-summary
Company Details
9975 Summers Ridge Road , SAN DIEGO CA : 92121
stock-summary
Tel: 1 858 55211001 858 6468023
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 98 Schemes (66.37%)

Foreign Institutions

Held by 140 Foreign Institutions (12.36%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Kenneth Buechler
Independent Chairman of the Board
Mr. Douglas Bryant
President, Chief Executive Officer, Director
Ms. Ann Rhoads
Director
Mr. Edward Michael
Independent Director
Ms. Kathy Ordonez
Independent Director
Dr. Mary Polan
Independent Director
Mr. Charles Slacik
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
615 Million
(Quarterly Results - Jun 2025)
Net Profit:
-255 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,933 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.89

stock-summary
Return on Equity

-3.37%

stock-summary
Price to Book

0.69